PURPOSE: We aimed to evaluate the impact of the primary Gleason pattern on biochemical recurrence-free survival (RFS) after radical prostatectomy (RP) in a single-center cohort of patients with Gleason 7 tumors. MATERIALS AND METHODS: From 1998 to 2008, 2,239 consecutive patients underwent RP for a localized prostate cancer. A total of 1,248 patients with Gleason score (GS) 7 cancers were included. Follow-up was standardized for all patients and recorded into a prospective database. Median postoperative follow-up was 23.4 months. Biochemical recurrence was defined by prostate-specific antigen level > 0.2 ng/ml. RESULTS: In all, 721 patients (57.8%) had a final GS of 3 + 4 and 527 (42.2%) of 4 + 3. Patients with GS 4 + 3 had a significantly higher risk of biochemical progression than those with GS 3 + 4 (P < 0.001). The 3- and 5-year biochemical RFS for Gleason score 3 + 4 cancers was 84.6 and 76.4%, respectively, versus 69.9 and 61.1% in Gleason score 4 + 3 cancers. Multivariate analysis showed that the primary Gleason remained statistically predictive for PSA failure (P = 0.018). When analysis was stratified by both pathologic stage and margin status, predictive value of primary Gleason was significant in pT2R0, pT3-4R0, and pT3-4R1 cancers, whereas survival curves were not statistically different in pT2R1 cancers (P = 0.672). CONCLUSION: Primary Gleason 4 pattern is an independent predictor for PSA failure. Analysis of Gleason patterns provides clinically relevant prognostic information, which may assist in the management of patients with Gleason score 7 cancers.
PURPOSE: We aimed to evaluate the impact of the primary Gleason pattern on biochemical recurrence-free survival (RFS) after radical prostatectomy (RP) in a single-center cohort of patients with Gleason 7 tumors. MATERIALS AND METHODS: From 1998 to 2008, 2,239 consecutive patients underwent RP for a localized prostate cancer. A total of 1,248 patients with Gleason score (GS) 7 cancers were included. Follow-up was standardized for all patients and recorded into a prospective database. Median postoperative follow-up was 23.4 months. Biochemical recurrence was defined by prostate-specific antigen level > 0.2 ng/ml. RESULTS: In all, 721 patients (57.8%) had a final GS of 3 + 4 and 527 (42.2%) of 4 + 3. Patients with GS 4 + 3 had a significantly higher risk of biochemical progression than those with GS 3 + 4 (P < 0.001). The 3- and 5-year biochemical RFS for Gleason score 3 + 4 cancers was 84.6 and 76.4%, respectively, versus 69.9 and 61.1% in Gleason score 4 + 3 cancers. Multivariate analysis showed that the primary Gleason remained statistically predictive for PSA failure (P = 0.018). When analysis was stratified by both pathologic stage and margin status, predictive value of primary Gleason was significant in pT2R0, pT3-4R0, and pT3-4R1 cancers, whereas survival curves were not statistically different in pT2R1 cancers (P = 0.672). CONCLUSION: Primary Gleason 4 pattern is an independent predictor for PSA failure. Analysis of Gleason patterns provides clinically relevant prognostic information, which may assist in the management of patients with Gleason score 7 cancers.
Authors: Stephen J Freedland; Elizabeth B Humphreys; Leslie A Mangold; Mario Eisenberger; Alan W Partin Journal: J Urol Date: 2006-10 Impact factor: 7.450
Authors: Jonathan L Wright; Claudia A Salinas; Daniel W Lin; Suzanne Kolb; Joseph Koopmeiners; Ziding Feng; Janet L Stanford Journal: J Urol Date: 2009-12 Impact factor: 7.450
Authors: Hong Gee Sim; Donatello Telesca; Stephen H Culp; William J Ellis; Paul H Lange; Lawrence D True; Daniel W Lin Journal: J Urol Date: 2008-03-17 Impact factor: 7.450
Authors: Marbele S Guimaraes; Maisa M Quintal; Luciana R Meirelles; Luis A Magna; Ubirajara Ferreira; Athanase Billis Journal: Int Braz J Urol Date: 2008 Jan-Feb Impact factor: 1.541
Authors: Kris K Rasiah; Phillip D Stricker; Anne-Maree Haynes; Warick Delprado; Jennifer J Turner; David Golovsky; Phillip C Brenner; Raji Kooner; Gordon F O'Neill; John J Grygiel; Robert L Sutherland; Susan M Henshall Journal: Cancer Date: 2003-12-15 Impact factor: 6.860
Authors: Jennifer R Stark; Sven Perner; Meir J Stampfer; Jennifer A Sinnott; Stephen Finn; Anna S Eisenstein; Jing Ma; Michelangelo Fiorentino; Tobias Kurth; Massimo Loda; Edward L Giovannucci; Mark A Rubin; Lorelei A Mucci Journal: J Clin Oncol Date: 2009-05-11 Impact factor: 44.544
Authors: Andrea Salonia; Firas Abdollah; Umberto Capitanio; Andrea Gallina; Nazareno Suardi; Alberto Briganti; Giuseppe Zanni; Matteo Ferrari; Fabio Castiglione; Maria Chiara Clementi; Patrizio Rigatti; Francesco Montorsi Journal: World J Urol Date: 2012-03-24 Impact factor: 4.226
Authors: R Mathieu; M Moschini; B Beyer; K M Gust; T Seisen; A Briganti; P Karakiewicz; C Seitz; L Salomon; A de la Taille; M Rouprêt; M Graefen; S F Shariat Journal: Prostate Cancer Prostatic Dis Date: 2017-01-10 Impact factor: 5.554
Authors: Ahva Shahabi; Raj Satkunasivam; Inderbir S Gill; Gary Lieskovsky; Sia Daneshmand; Jacek K Pinski; Mariana C Stern Journal: Can Urol Assoc J Date: 2016-01-14 Impact factor: 1.862
Authors: Marina França de Resende; Samantha Vieira; Ludmilla Thomé Domingos Chinen; Francesco Chiappelli; Francisco Paulo da Fonseca; Gustavo Cardoso Guimarães; Fernando Augusto Soares; Ivan Neves; Simone Pagotty; Peter A Pellionisz; Andre Barkhordarian; Xenia Brant; Rafael Malagoli Rocha Journal: J Transl Med Date: 2013-02-11 Impact factor: 5.531